Abstract
The protein tyrosine phosphatase family (PTP) contains a group of dual-specificity phosphatases (DUSPs) that regulate the activivity of MAP kinases (MAPKs), which are key effectors in the control of cell growth and survival in physiological and pathological processes, including cancer. These phosphatases, named as MKP-DUSPs, include the MAPK phosphatases (MKPs) as well as a group of small-size atypical DUSPs structurally and functionally related to the MKPs. MKP-DUSPs, in most of the cases, are direct inactivators of MAPKs by dephosphorylation of both the Thr and the Tyr regulatory residues at the MAPKs catalytic loop. In some other cases, MKPDUSPs regulate the activity of MAPKs indirectly, acting through upstream MAPK pathways components. The active involvement of MKP-DUSPs in oncogenesis or resistance to cancer therapies is now well documented, making the search and validation of MKP-DUSPs inhibitors a prominent area in clinical cancer research. Here, we review the current knowledge on the role of MKP-DUSPs in human cancer, the status of the preclinical development and validation of specific MKP-DUSP inhibitors, and the potential of MKP-DUSPs as targets for anti-cancer drugs.
Keywords: Protein tyrosine phosphatases (PTPs), dual-specificity phosphatases (DUSPs), MAP kinase phosphatases (MKPs), inhibitors, anti-cancer agents, JNK1, VRK3, ERK1/2, dual specificity, LNCaP, PMA
Anti-Cancer Agents in Medicinal Chemistry
Title: Dual-Specificity MAP Kinase Phosphatases as Targets of Cancer Treatment
Volume: 11 Issue: 1
Author(s): Caroline Nunes-Xavier, Carlos Roma-Mateo, Pablo Rios, Celine Tarrega, Rocio Cejudo-Marin, Lydia Tabernero and Rafael Pulido
Affiliation:
Keywords: Protein tyrosine phosphatases (PTPs), dual-specificity phosphatases (DUSPs), MAP kinase phosphatases (MKPs), inhibitors, anti-cancer agents, JNK1, VRK3, ERK1/2, dual specificity, LNCaP, PMA
Abstract: The protein tyrosine phosphatase family (PTP) contains a group of dual-specificity phosphatases (DUSPs) that regulate the activivity of MAP kinases (MAPKs), which are key effectors in the control of cell growth and survival in physiological and pathological processes, including cancer. These phosphatases, named as MKP-DUSPs, include the MAPK phosphatases (MKPs) as well as a group of small-size atypical DUSPs structurally and functionally related to the MKPs. MKP-DUSPs, in most of the cases, are direct inactivators of MAPKs by dephosphorylation of both the Thr and the Tyr regulatory residues at the MAPKs catalytic loop. In some other cases, MKPDUSPs regulate the activity of MAPKs indirectly, acting through upstream MAPK pathways components. The active involvement of MKP-DUSPs in oncogenesis or resistance to cancer therapies is now well documented, making the search and validation of MKP-DUSPs inhibitors a prominent area in clinical cancer research. Here, we review the current knowledge on the role of MKP-DUSPs in human cancer, the status of the preclinical development and validation of specific MKP-DUSP inhibitors, and the potential of MKP-DUSPs as targets for anti-cancer drugs.
Export Options
About this article
Cite this article as:
Nunes-Xavier Caroline, Roma-Mateo Carlos, Rios Pablo, Tarrega Celine, Cejudo-Marin Rocio, Tabernero Lydia and Pulido Rafael, Dual-Specificity MAP Kinase Phosphatases as Targets of Cancer Treatment, Anti-Cancer Agents in Medicinal Chemistry 2011; 11 (1) . https://dx.doi.org/10.2174/187152011794941190
DOI https://dx.doi.org/10.2174/187152011794941190 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Alternative Gene Therapy Strategies for the Repair of Craniofacial Bone Defects
Current Gene Therapy Medicinal Compound Celastrol As a Potential Clinical Anticancer Drug: Lessons Learned From Preclinical Studies
Clinical Cancer Drugs Human Amniotic Membrane: Clinical Uses, Patents And Marketed Products
Recent Patents on Regenerative Medicine Nuclear Hormone Receptors and Female Reproduction
Current Molecular Medicine Colchicine, Biologic Agents and More for the Treatment of Familial Mediterranean Fever. The Old, the New, and the Rare
Current Medicinal Chemistry The Safety of Medications for the Treatment of Bipolar Disorder During Pregnancy and the Puerperium
Current Drug Safety Hypocholesterolemia
Current Vascular Pharmacology Cancer Bioinformatics for Updating Anticancer Drug Developments and Personalized Therapeutics
Reviews on Recent Clinical Trials Modern Perspectives on the Structure, Function and Evolution of the Relaxin-Like Peptides and their Receptors
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Are Anti-Angiogenic Drugs Useful in Neurodegenerative Disorders?
CNS & Neurological Disorders - Drug Targets Clinical Analysis Methods of Voice Disorders
Current Bioinformatics Growth Differentiation Factor 5 Regulation in Bone Regeneration
Current Pharmaceutical Design Is there a Teratogenicity Risk Associated with Cannabis and Synthetic Cannabimimetics’ (‘Spice’) Intake?
CNS & Neurological Disorders - Drug Targets Ibubrofen in the Treatment of Patent Ductus Arteriosus in Preterm Infants: What We Know, What We Still Do Not Know
Current Pharmaceutical Design The Role of Therapeutic Drugs on Acquired Mitochondrial Toxicity
Current Drug Metabolism A Survey on Synthesis Processes of Structured Materials for Biomedical Applications: Iron-based Magnetic Nanoparticles, Polymeric Materials and Polymerization Processes
Current Pharmaceutical Design Vasculogenesis: Making Pipes for the Cardiovascular Plumbing
Current Angiogenesis (Discontinued) Pediatrics for Disability: A Comprehensive Approach to Children with Syndromic Psychomotor Delay
Current Pediatric Reviews Metallothionein as a Scavenger of Free Radicals - New Cardioprotective Therapeutic Agent or Initiator of Tumor Chemoresistance?
Current Drug Targets Polysaccharide-Based Nanobiomaterials as Controlled Release Systems for Tissue Engineering Applications
Current Pharmaceutical Design